Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

GNPS - HNRC sample co-migration with drug microbial incubations

ABSTRACT: HNRC sample spiked by drug microbial incubations to check retention time match of drug microbial metabolites

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Pieter C. Dorrestein

PROVIDER: MSV000096013 | GNPS | Wed Oct 02 20:54:00 BST 2024

REPOSITORIES: GNPS

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

20240930 HNRC sample HIV drug co-migration

Project description:Retention time check by co-migration of HIV drug standards with fecal samples from the HNRC cohort.

| MSV000095996 | MassIVE

GNPS - 20240930 HNRC sample HIV drug co-migration

Project description:Retention time check by co-migration of HIV drug standards with fecal samples from the HNRC cohort.

| MSV000095996 | GNPS

20240814 HNRC drug microbial culture co-migration

Project description:Co-migration / spiking experiment to confirm the retention time of drug analogs detected in HNRC fecal samples with those in microbial cultures

2024-08-14 | MSV000095606 | MassIVE

GNPS - HNRC samples co-analyzed with drug microbial incubation (MSV000095331)

Project description:HNRC samples co-analyzed with drug microbial incubation (MSV000095331) for retention time matching with drug microbial metabolites

2024-10-02 | MSV000096012 | GNPS

GNPS - 20240814 HNRC drug microbial culture co-migration

Project description:Co-migration / spiking experiment to confirm the retention time of drug analogs detected in HNRC fecal samples with those in microbial cultures

2024-08-14 | MSV000095606 | GNPS

Predicting and manipulating drug inactivation by the human gut microbiome

Project description:The trillions of microorganisms in the human gastrointestinal tract are an underexplored aspect of pharmacology. Despite numerous examples of microbial effects on drug efficacy and toxicity, there is often an incomplete understanding of the underlying mechanisms. Here, we dissect the inactivation of the commonly prescribed cardiac glycoside, digoxin, by Eggerthella lenta. Whole genome transcriptional profiling, comparative genomics, and culture-based assays revealed a cytochrome-encoding operon up-regulated by digoxin, absent in non-metabolizing E. lenta strains, and predictive of the efficiency of digoxin inactivation by the human gut microbiome. Digoxin inactivation was further enhanced by microbial interactions and inhibited by arginine. Pharmacokinetic studies using gnotobiotic mice revealed that increasing dietary protein reduces the in vivo metabolism of digoxin by E. lenta, with significant changes to drug concentration in the urine and serum. These results emphasize the importance of viewing pharmacology from the perspective of both our human and microbial genomes. RNA-Seq analysis of Eggerthella lenta cultured with or without digoxin.

2013-06-15 | E-GEOD-43919 | biostudies-arrayexpress

High-Throughput Measurement and Machine Learning-Based Prediction of Collision Cross Sections for Drugs and Drug Metabolites

Project description:High-throughput IM-MS analysis of drug metabolism incubations prepared from the MicroSource Spectrum Discovery Collection using pooled human liver microsomes and S9 fraction

2021-12-09 | MSV000088549 | MassIVE

Predicting and manipulating drug inactivation by the human gut microbiome

2013-06-15 | GSE43919 | GEO

Impact of Microbiome on Hepatic Drug Processing Genes in Mice during Pregnancy

Project description:While microbiome and pregnancy are known to alter drug disposition, the interplay of the two physiological factors to impact expression and/or activity of drug processing genes (DPGs) has yet to be elucidated. This study aimed to investigate the effects of microbiome on host hepatic DPGs during pregnancy using conventional (CV) and germ-free (GF) mice. Four groups of female mice were used, namely CV non-pregnant (CVNP), GF non-pregnant (GFNP), CV pregnant (CVP), and GF pregnant (GFP) mice. Pregnant mice examined were on gestation day 15. Transcriptomic and targeted proteomics of hepatic DPGs were profiled using a multi-omics approach. Plasma bile acid and steroid hormone levels were quantified using LC-MS/MS. Cyp3a activities were measured by mouse liver microsome incubations. While the overall trend in pregnancy-induced changes in the expression or activity of hepatic DPGs in CV and GF mice was similar, significant differences in the magnitude of changes were observed. For certain genes, we noticed opposite effects of pregnancy on mRNA and protein expression of DPGs in both CV and GF mice. For instance, the mRNA levels of Cyp3a11, the murine homolog of human CYP3A4, were decreased by 1.7-fold and 3.3-fold by pregnancy in CV and GF mice, respectively. However, the protein levels of Cyp3a11 were increased similarly ~2-fold by pregnancy in both CV and GF mice. Yet, microsome incubations revealed a marked induction of Cyp3a activity by pregnancy that was >5-fold greater in CV mice than that in GF mice. Plasma bile acid and steroid hormone levels were also significantly altered by microbiome and pregnancy, respectively, which may contribute to the differential effects of pregnancy in CV and GF mice. This is the first study to show that microbiome can alter hepatic DPGs in pregnancy.

2020-08-26 | GSE143391 | GEO